Additive Value of [<sup>68</sup>Ga]Ga-RM26 PET/CT to [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study

Lymph node staging in prostate cancer is crucial for treatment and prognosis, yet [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT has limited sensitivity in detecting pelvic lymph node metastasis (PLNM). [<sup>68</sup>Ga]Ga-RM26 PET/CT, targeting the gastrin-releasing peptide receptor, complements [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT in assessing primary tumor extension and aggressiveness. However, its role in detecting PLNM and complementing [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT remains underexplored. <b>Methods:</b> This prospective study enrolled newly diagnosed yet untreated prostate cancer patients who underwent [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT, followed by radical prostatectomy and extended pelvic lymph node dissection. The primary objective was to evaluate the diagnostic performance of both PET/CT modalities in detecting PLNM. <b>Results:</b> In total, 68 patients were enrolled, with a 30.9% (21/68) pathologic PLNM rate. In patient-based analysis, [<sup>68</sup>Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.43 and 0.94, respectively, compared with 0.52 and 0.89 for [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. [<sup>68</sup>Ga]Ga-RM26 PET/CT detected additional PLNMs in 50% (5/10) of patients that were missed by [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. The combined use of [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT resulted in sensitivity of 0.76 and specificity of 0.85. In total, 1,049 lymph nodes were dissected, including 991 normal and 58 positive nodes. In lesion-based analysis, [<sup>68</sup>Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.38 and 0.99, respectively, compared with 0.5 and 0.99 for [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. [<sup>68</sup>Ga]Ga-RM26 PET/CT identified 41.4% (12/29) of pathologic positive nodes missed by [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. The combined [<sup>68</sup>Ga]Ga-RM26 and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT demonstrated sensitivity of 0.71 and specificity of 0.99. <b>Conclusion:</b> In dual-target imaging, [<sup>68</sup>Ga]Ga-RM26 PET/CT identified additional PLNMs. The combination of [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT achieved higher diagnostic sensitivity with minimal loss of specificity.

Authors

Institutions

Publication Details

Journal
Journal of Nuclear Medicine
Published
2025-03-20
DOI
https://doi.org/10.2967/jnumed.124.269189
Citations
3
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
4.56

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Additive Value of [68Ga]Ga-RM26 PET/CT to [68Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study

Xiaomei Gao, Yongxiang Tang, Shuo Hu, Yi Cai et al.
3 citations
Journal of Nuclear Medicine
Prostate Cancer Treatment and Research
4.56
article

Additive Value of [68Ga]Ga-RM26 PET/CT to [68Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study

Xiaomei Gao, Yongxiang Tang, Shuo Hu, Yi Cai, Wei Tang, Lin Qi, Ye Zhang, Minfeng Chen
article en
3 citations

Abstract

Lymph node staging in prostate cancer is crucial for treatment and prognosis, yet [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT has limited sensitivity in detecting pelvic lymph node metastasis (PLNM). [<sup>68</sup>Ga]Ga-RM26 PET/CT, targeting the gastrin-releasing peptide receptor, complements [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT in assessing primary tumor extension and aggressiveness. However, its role in detecting PLNM and complementing [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT remains underexplored. <b>Methods:</b> This prospective study enrolled newly diagnosed yet untreated prostate cancer patients who underwent [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT, followed by radical prostatectomy and extended pelvic lymph node dissection. The primary objective was to evaluate the diagnostic performance of both PET/CT modalities in detecting PLNM. <b>Results:</b> In total, 68 patients were enrolled, with a 30.9% (21/68) pathologic PLNM rate. In patient-based analysis, [<sup>68</sup>Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.43 and 0.94, respectively, compared with 0.52 and 0.89 for [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. [<sup>68</sup>Ga]Ga-RM26 PET/CT detected additional PLNMs in 50% (5/10) of patients that were missed by [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. The combined use of [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT resulted in sensitivity of 0.76 and specificity of 0.85. In total, 1,049 lymph nodes were dissected, including 991 normal and 58 positive nodes. In lesion-based analysis, [<sup>68</sup>Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.38 and 0.99, respectively, compared with 0.5 and 0.99 for [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. [<sup>68</sup>Ga]Ga-RM26 PET/CT identified 41.4% (12/29) of pathologic positive nodes missed by [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. The combined [<sup>68</sup>Ga]Ga-RM26 and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT demonstrated sensitivity of 0.71 and specificity of 0.99. <b>Conclusion:</b> In dual-target imaging, [<sup>68</sup>Ga]Ga-RM26 PET/CT identified additional PLNMs. The combination of [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT achieved higher diagnostic sensitivity with minimal loss of specificity.

Journal of Nuclear MedicineVol. 66(5)
Central South University (CN), National Health and Family Planning Commission (CN), National Clinical Research (US), Xiangya Hospital Central South University (CN)
National Natural Science Foundation of China, Central South University, China Postdoctoral Science Foundation, Xiangya Hospital, Central South University, Fundamental Research Funds for the Central Universities
Good health and well-being
Openalex Percentile: Top 6%
Prostate Cancer Treatment and Research
4.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.